Organoids and genome repair / Illustrative model
Read the joint-endpoint audit
Separate repair endpoints do not establish joint success
The illustrative endpoint counts are synthetic. Allele, cell and tissue-area denominators cannot be silently combined.
# One construct must meet its required endpoints together AI-assisted research engineering, 2026-10-19. This connects the stem-cell, organoid and genome-repair goals to the full dental and whole-body repair checklist. It adds a joint-endpoint audit; it does not claim a repaired organ. ## Existing work and the added question The public [base-editing-evidence project](https://github.com/dylanstechmann/base-editing-evidence) already distinguishes reached cells, edited products and target-population coverage. Its local README was inspected read-only; no code or evidence from that project was copied into this repository or changed. The workbench's [PDL endpoint contract](../../organoid/periodontal-ligament-interface/endpoint_contract.tsv) already requires both fiber insertions, viable identity, no mineral bridge, mechanics and durability. We extend the integration question: **are the required outcomes present in the same target tissue, at the same time?** Separate marginal success percentages cannot establish their overlap. An editing allele fraction, perfused area and lineage-positive cell fraction also cannot be multiplied as though they shared a denominator. ## Executed audit In an explicitly synthetic set of 100 equal-volume registered target regions, 80, 90, 75 and 70 meet four declared criteria. With no overlap observations, the possible joint count is **15–70**, not a known 37.8. The latter is only an independence-product benchmark. A second fixture intentionally substitutes an allele denominator: the audit returns an unidentified result. A third fixture supplies a synthetic measured joint count of 40, which is compatible with the bounds. None of these counts describes real cells or organoids. For N shared units and k endpoint-attainment counts n_i, the exact marginal overlap bounds are max(0, sum(n_i)−(k−1)N) and min(n_i). The audit requires an explicit shared population, sampling frame, unit, count and timepoint. Missing endpoints stay unknown. Different-unit measurements require a validated crosswalk before they can become shared-unit observations. These bounds concern declared assay criteria, not validated functional repair. Six tests include an exhaustive 4-unit/3-endpoint overlap oracle, denominator and time mismatch rejection, missingness, inconsistent joint counts and invalid inputs. The implementation assumes exact counts in a fixed set: it does not propagate assay error, sampling uncertainty or spatial dependence. A marker criterion cannot become a functional one just by passing this audit. ## Source-qualified transfer limits Quintard et al. established intravascular perfusion in blood-vessel organoids-on-chip and examined pancreatic islet spheroid function. This is a useful transport chassis, not a demonstration of a genetically corrected, innervated tooth attachment or organ replacement. [Primary study](https://doi.org/10.1038/s41467-024-45710-4). The initial patient-specific CPS1 base-editing report concerns one infant and a known liver-disease variant with short initial follow-up. It supplies a clinical delivery/response precedent, not identification or correction of distributed ordinary-aging variants across organs. [Original report](https://doi.org/10.1056/NEJMoa2504747). The newly qualified [MOTS-c stem-cell counterevidence](../compounds/REPORT.md) is relevant when selecting functional endpoints: pathway engagement must be paired with cell state and repair outcomes. Consult that report's exact source, donor design and animal-model limitations. ## Next integrated research packet 1. Declare a relevant causal lesion if editing is proposed, the target lineage/compartment, comparator and functional deficit. Keep ordinary aging separate from a monogenic disease model. 2. Qualify assays and matched reference distributions for each endpoint. Preserve intended-only products, structural/RNA outcomes where relevant, identity, proliferation/clone behavior and adverse outcomes separately. 3. Register comparable target regions or traceable constructs. Measure perfusion and viability, then the tissue-specific interface/function on the same sampling frame. Destructive measurements require a validated pairing/crosswalk or remain separate observations. 4. Report joint attainment where observed, marginal bounds where identifiable and unknowns otherwise. Keep constructs and fields nested in donor, clone and manufacturing batch; this audit does not create independent donors. 5. Test persistence after intervention withdrawal. For dental attachment, intended pose after finite support ends, physiological mobility and no ankylosis/resorption remain distinct requirements. A chip cannot satisfy retained-tooth positional durability. The immediate useful next input is a paired, traceable construct-level dataset with calibrated perfusion, identity and functional-interface outcomes. Do not choose editing targets, numerical repair thresholds or a delivery formulation from the synthetic example. This is a measurement/integration specification, not a wet-lab or human-treatment protocol. ## Reproduce ```text python studies/checklist-progress-2026-10-19/integration/audit_joint_endpoints.py python -m unittest discover -s tests -p test_joint_regeneration_endpoints.py -v ``` The [fixtures](joint_endpoint_examples.json) and [hash-linked audit output](derived/joint_endpoint_audit.json) are public, synthetic and contain no personal data. No organoid, animal or person was treated, and no sibling repository was modified.